

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 November 2017 (23.11.2017)



(10) International Publication Number
WO 2017/201200 A8

(51) International Patent Classification:

A61K 31/07 (2006.01) *A61P 35/00* (2006.01)
A61K 31/203 (2006.01)

(21) International Application Number:

PCT/US2017/033172

(22) International Filing Date:

17 May 2017 (17.05.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/338,883 19 May 2016 (19.05.2016) US

(71) Applicant: ORPHAGEN PHARMACEUTICALS, INC.
[US/US]; 11558 Sorrento Valley Road, Suite 4, San Diego,
CA 92121 (US).

(72) Inventors: THACHER, Scott, McNear; 11558 Sorren-
to Valley Road, Suite 4, San Diego, CA 92121 (US).
CROWE, Paul, Damian; 11558 Sorrento Valley Road,
Suite 4, San Diego, CA 92121 (US). TAO, Haiyan; 11558
Sorrento Valley Road, Suite 4, San Diego, CA 92121 (US).
RAHEJA, Raj, Kumar; 11558 Sorrento Valley Road,
Suite 4, Sa Diego, CA 92121 (US).

(74) Agent: MALLON, Joseph, J.; Knobbe, Martens, Olson &
Bear, Llp, 2040 Main Street, 14th Floor, Irvine, CA 92614
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR,
KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

28 December 2017 (28.12.2017)

(54) Title: THERAPEUTIC COMPOSITIONS CONTAINING RAR-ALPHA ANTAGONISTS

E.




Figure 11.

(57) Abstract: Provided are methods associated with the use of selective retinoic acid receptor (RAR) antagonists, such as RAR α -selective antagonists, for single-agent therapy or combination cancer, tumor or tumor metastases therapy

(15) Information about Correction:

see Notice of 28 December 2017 (28.12.2017)